Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of Danaher Corp. slipped 5.54% to $186.81 Wednesday, on what proved to be an all-around poor trading session for the ...

Danaher Corporation DHR has been benefiting from strength in its bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in North America, Europe ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...

Danaher Corp. closed 34.49% below its 52-week high of $281.70, which the company achieved on August 1st.

Vietnam emerges as the fastest-growing market, bolstered by strong primary healthcare enhancements. The infectious disease ...

Danaher Corporation, a key player in Life Sciences, Biotechnology, and Diagnostics, has shown mixed financial performance with recent declines in revenue and net earnings. Despite recent struggles ...

Sept 14 (Reuters) - Danaher Corp (DHR.N), opens new tab said on Wednesday it would separate its environmental & applied solutions (EAS) segment to pivot growth towards the medical technology firm ...

Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent.

Last week, readers were most interested in a story about what's up Roche's sleeve as it talked about its plans during its investor day.